Drug Approval | January 20, 2022
Australia grants provisional registration for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
The study will be published on the pre-print server, medRXiv, shortly
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
